Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440940 | 0.95 | MAOB (0.63) | MAOBAPPHRH3NR4A2CA12 | |
| SCHEMBL16440935 | 0.90 | MAOB (0.61) | MAOBAPPNPC1RAB9ANR4A2 | |
| SCHEMBL16428970 | 0.89 | HRH3 (0.54) | HRH3RAB9ABCHELTA4HEPHX2 | |
| SCHEMBL8990705 | 0.85 | CYP2D6 (0.54) | — | |
| SCHEMBL10339674 | 0.85 | HRH3 (0.61) | HRH3RAB9ABCHELTA4HEPHX2 | |
| SCHEMBL16440939 | 0.85 | MAOB (0.67) | MAOBAPPHRH3NR4A2CA12 | |
| SCHEMBL3601077 | 0.85 | RARB (0.56) | MAOBCA1CA2 | |
| SCHEMBL8990715 | 0.83 | RARB (0.55) | MAOBCA1CA2 | |
| SCHEMBL16440936 | 0.81 | FFAR1 (0.54) | MAOBAPPHRH3BCHELTA4H | |
| SCHEMBL16428800 | 0.81 | FFAR1 (0.54) | MAOBAPPHRH3BCHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957213-B2 | Organic compound, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-9957213-B2 | Organic compound, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20150034870-A1 | ORGANIC COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| US-20150034870-A1 | ORGANIC COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150034870-A1 | ORGANIC COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | AR, OCIAD1, RCC2 | MAOB 2243/4885APP 871/4885HRH3 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.